Ziftomenib: 2022 MOTY Nominee
Kura Oncology menin-MLL1 inhibitor
oral, QD menin-MLL1 inhibitor Ph. I/II for leukemia from HTS and SBDD ziftomenib (KO-539) Kura Oncology, San Diego, CA / UMich (Grembecka Lab)
Other molecules you may be interested in
NX-1607
Nurix Therapeutics’ NX-1607 is the first oral small molecule inhibitor of CBL-B to enter clinical trials. CBL-B negatively regulates immune activation in T, B, and NK cells; while immune checkpoint inhibitors are often effective, they have limitations, including lack of efficacy in certain cancers, patient variability, and resistance. NX-1607 enhances T cell activation by gluing CBL-B in an inactive conformation and, driven by preclincial data, NX-1607 is currently in a Ph. I trial. This article details its discovery story and initial clincial results, presented at the ACS Spring 2024 meeting.
vactosertib
Vactosertib is an orally bioavailable TGFβ type I receptor kinase inhibitor, that has demonstrated safety, tolerability, and clinical efficacy in combination with pomalidomide in a Ph. Ib trial for RRMM.
VVD-214/RO7589831
VVD-214/RO7589831 is an oral covalent, reversible, and allosteric inhibitor of WRN helicase discovered by the San Diego-based biotech Vividion Therapeutics and being developed by Roche for tumors marked by microsatellite instability and/or mismatch repair deficiency. Vividion has utilized its chemoproteomics platform to discover and develop novel treatment options for oncology targets. The structure and initial preclinical pharmacology data for VVD-214 were recently disclosed at the AACR Annual Meeting 2024 in San Diego. VVD-214 is currently being evaluated in a Ph. I trial.
casdatifan (AB521)
Arcus Biosciences recently disclosed the structure and discovery story of their oral HIF-2α inhibitor casdatifan (AB521) at the ACS Fall 2024 First Time Disclosures session in Denver. Read on to find out how the team overcame serum shifts and metabolism issues to deliver into the clinic what could potentially be a best-in-class compound, superior to the recently approved inhibitor, belzutifan.
PLX-4545
PLX-4545 is an oral CRBN-based molecular glue degrader of IKZF2 in Ph. I trials. It potentially addresses anti-tumor immunity suppression within the TME, critical in checkpoint blocker resistance. Tumors use IKZF2 to regulate the function of regulatory T cells and inhibit effector T cells. IKZF2 depletion in regulatory T cells enhances the anti-tumor response. The discovery and structural data of PLX-4545 were presented by Kevin Freeman-Cook at the ACS Fall 2024 First-Time Disclosures session in Denver, CO. We are reporting the discovery story and its potential impact on immuno-oncology.